FDA Grants Approval for New Oral Plaque Psoriasis Medication

The U.S. FDA has approved ICOTYDE™ (icotrokinra), a new oral medication for plaque psoriasis, a condition impacting up to 80% of psoriasis patients. This approval, based on positive Phase 3 study results involving over 2,500 patients, introduces an additional treatment option with demonstrated clinical efficacy and safety.